Literature DB >> 25628310

Translating the transcriptome into tools for the early detection and prevention of lung cancer.

Yaron B Gesthalter1, Jessica Vick2, Katrina Steiling3, Avrum Spira3.   

Abstract

Despite advances in the management of lung cancer, this disease remains a significant global health burden with survival rates that have not significantly improved in decades. The mortality reduction achieved by low-dose helical CT (LDCT) screening of select high-risk patients is challenged by the high false positive rate of this screening modality and the potential for morbidity associated with follow-up diagnostic evaluation in patients with high risk for iatrogenic complications. The diagnostic dilemma of the indeterminate nodule incidentally identified on diagnostic or screening CT has created a need for reliable biomarkers capable of distinguishing benign from malignant disease. Furthermore, there is an urgent need to develop molecular biomarkers to supplement clinical risk models in order to identify patients at highest risk for having an early stage lung cancer that may derive the greatest benefit from LDCT screening, as well as identifying patients at high-risk for developing lung cancer that may be candidates for emerging chemopreventive strategies. Evolving bioinformatic techniques and the application of these algorithms to analyse the transcriptomic changes associated with lung cancer promise translational discoveries that can bridge these large clinical gaps. The identification of lung cancer associated transcriptomic alterations in readily accessible tissue sampling sites offers the potential to develop early diagnostic and risk stratification strategies applicable to large populations. This review summarises the challenges associated with the early detection, screening and chemoprevention of lung cancer with an emphasis on how genomic information encapsulated by the transcriptome can facilitate future innovations in these clinical settings. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Lung Cancer; Lung Cancer Chemotherapy; Tobacco and the lung

Mesh:

Year:  2015        PMID: 25628310     DOI: 10.1136/thoraxjnl-2014-206605

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

Review 1.  Risk factors assessment and risk prediction models in lung cancer screening candidates.

Authors:  Mariusz Adamek; Ewa Wachuła; Sylwia Szabłowska-Siwik; Agnieszka Boratyn-Nowicka; Damian Czyżewski
Journal:  Ann Transl Med       Date:  2016-04

Review 2.  [Lung cancer screening - risk stratification : Who should undergo screening?].

Authors:  L Beer; H Prosch
Journal:  Radiologe       Date:  2016-09       Impact factor: 0.635

3.  Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway.

Authors:  Yasminka Jakubek; Wenhua Lang; Selina Vattathil; Melinda Garcia; Li Xu; Lili Huang; Suk-Young Yoo; Li Shen; Wei Lu; Chi-Wan Chow; Zachary Weber; Gareth Davies; Jing Huang; Carmen Behrens; Neda Kalhor; Cesar Moran; Junya Fujimoto; Reza Mehran; Randa El-Zein; Stephen G Swisher; Jing Wang; Jerry Fowler; Avrum E Spira; Erik A Ehli; Ignacio I Wistuba; Paul Scheet; Humam Kadara
Journal:  Cancer Res       Date:  2016-05-23       Impact factor: 12.701

4.  Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases.

Authors:  Yingjia Sun; Xinghao Ai; Shengping Shen; Linping Gu; Shun Lu
Journal:  Patient Prefer Adherence       Date:  2015-08-12       Impact factor: 2.711

Review 5.  Microarray Meta-Analysis and Cross-Platform Normalization: Integrative Genomics for Robust Biomarker Discovery.

Authors:  Christopher J Walsh; Pingzhao Hu; Jane Batt; Claudia C Dos Santos
Journal:  Microarrays (Basel)       Date:  2015-08-21

6.  Impact of sex, body mass index and initial pathologic diagnosis age on the incidence and prognosis of different types of cancer.

Authors:  Xuan Huang; Chuanjun Shu; Li Chen; Bing Yao
Journal:  Oncol Rep       Date:  2018-06-27       Impact factor: 3.906

Review 7.  The multifaceted roles of FOXM1 in pulmonary disease.

Authors:  Yumei Li; Feng Wu; Qi Tan; Mengfei Guo; Pei Ma; Xuan Wang; Shuai Zhang; Juanjuan Xu; Ping Luo; Yang Jin
Journal:  Cell Commun Signal       Date:  2019-04-16       Impact factor: 5.712

Review 8.  Recent advances in diagnostic technologies in lung cancer.

Authors:  Hye Jung Park; Sang Hoon Lee; Yoon Soo Chang
Journal:  Korean J Intern Med       Date:  2020-02-28       Impact factor: 2.884

9.  SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer.

Authors:  Lúcia L Correia; Jo-Anne Johnson; Peter McErlean; Julien Bauer; Hassan Farah; Doris M Rassl; Robert C Rintoul; Tariq Sethi; Paul Lavender; Emma L Rawlins; Trevor D Littlewood; Gerard I Evan; Frank M McCaughan
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

10.  Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.

Authors:  Qingzhou Guan; Haidan Yan; Yanhua Chen; Baotong Zheng; Hao Cai; Jun He; Kai Song; You Guo; Lu Ao; Huaping Liu; Wenyuan Zhao; Xianlong Wang; Zheng Guo
Journal:  BMC Genomics       Date:  2018-01-29       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.